… 3 trials in non-small cell
lung cancer (NSCLC) and has participated in … and 3rd line non-small cell
lung cancer (NSCLC) in combination with docetaxel … cell
lung cancer (NSCLC), which accounts for approximately 85 percent of all
lung cancer … anticancer agent in non-small cell
lung cancer. The Company is also planning …
No comments:
Post a Comment